Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma
Titel:
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma
Auteur:
Verlingue, Loic Italiano, Antoine Prenen, Hans Guerra Alia, Eva Maria Tosi, Diego Perets, Ruth Lugowska, Iwona Moiseyenko, Vladimir Gumus, Mahmut Arslan, Cagatay Lindsay, Colin R. Deva, Sanjeev Taus, Álvaro Oaknin, Ana Rottey, Sylvie Cicin, Irfan Goksu, Sema Sezgin Smolin, Alexey Roselló-Keränen, Susana Habigt, Christin Marbach, Daniel Boetsch, Christophe Dejardin, David Sleiman, Nassim Evers, Stefan Richard, Muriel Ardeshir, Caroline Charo, Jehad Kraxner, Anton Teichgräber, Volker Keshelava, Nino Dziadziuszko, Rafal